Shows
TMO EPM / Hemato H9J68 - Results of the Simultaneous Combination of Ponatinib and Blinatumomab in Philadelphia Chromosome-Positive Acute Lymphoblastic LeukemiaDiscussão do artigo: "Results of the Simultaneous Combination of Ponatinib and Blinatumomab in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia" de Kantarjian H JCO 2024Apresentado por: Dr. Matheus GarciaDiscussão por: Dr. Eduardo Burlamaqui , Dra. Ilana Barcessat, Dra. Amanda Chucre, Dr. Pedro Moraes e Dr. Vinícius Molla
2026-01-1133 min
TMO EPM / Hemato H9J67 - Long-Term (≥5-Year) Remission and Survival After Treatment With Ciltacabtagene Autoleucel in CARTITUDE-1 Patients With Relapsed/Refractory Multiple MyelomaDiscussão do artigo: "Long-Term (≥5-Year) Remission and Survival After Treatment With Ciltacabtagene Autoleucel in CARTITUDE-1 Patients With Relapsed/Refractory Multiple Myeloma" de Jagannath S JCO 2025Apresentado por: Dr. Guilherme RodriguesDiscussão por: Dr. Eduardo Burlamaqui, Dra. Ana Cecilia Bahia, Dr. Pedro Moraes e Dr. Vinícius Molla
2026-01-0724 min
TMO EPM / Hemato H9J66 - Three-year follow-up analysis of first-line axicabtagene ciloleucel for high-risk large B-cell lymphoma: the ZUMA-12 studyDiscussão do artigo: "Three-year follow-up analysis of first-line axicabtagene ciloleucel for high-risk large B-cell lymphoma: the ZUMA-12 study" de Chavez J blood 2025Apresentado por: Dra. Ilana Barcessat Discussão por: Dr. Rafael Faust , Dra. Ana Cecilia Bahia, Dr. Pedro Moraes e Dr. Vinícius Molla
2025-12-3026 min
TMO EPM / Hemato H9J65 - Acalabrutinib Plus Bendamustine-Rituximab in Untreated Mantle Cell LymphomaDiscussão do artigo: "Acalabrutinib Plus Bendamustine-Rituximab in Untreated Mantle Cell Lymphoma" de Wang M JCO 2025Apresentado por: Dra. Ana Cecilia BahiaDiscussão por: Dr. Gabriele Ritter, Dr. Matheus Garcia, Dr. Pedro Moraes e Dr. Vinícius Molla
2025-11-0533 min
TMO EPM / Hemato H9J64 - Graft-versus-Host Disease Prophylaxis with Cyclophosphamide and CyclosporinDiscussão do artigo: "Graft-versus-Host Disease Prophylaxis with Cyclophosphamide and Cyclosporin" de Curtis DJ NEJM 2025Apresentado por: Dr. Matheus GarciaDiscussão por: Dr. Gabrielle Ritter, Dra. Lais Vianna, Dr. Wallber Moraes, Dr. Pedro Moraes e Dr. Vinícius Molla
2025-11-0238 min
TMO EPM / Hemato H9J63 - Low rates of chronic graft-versus-host disease with ruxolitinib maintenance following allogeneic HCTDiscussão do artigo: "Low rates of chronic graft-versus-host disease with ruxolitinib maintenance following allogeneic HCT" de DeFilipp Blood 2025Apresentado por: Dra. Amanda ChucreDiscussão por: Dr. Eduardo Burlamaqui, Dr. Matheus Garcia, Dr. Pedro Moraes e Dr. Vinícius Molla
2025-09-0121 min
TMO EPM / Hemato H9J62 - Sequential Infusion of Mesenchymal Stem Cell for Graft-Versus-Host Disease Prevention in Haploidentical Hematopoietic Stem Cell TransplantationDiscussão do artigo: "Sequential Infusion of Mesenchymal Stem Cell for Graft-Versus-Host Disease Prevention in Haploidentical Hematopoietic Stem Cell Transplantation" de Yao H JCO 2025Apresentado por: Dra. Ana Cecilia BahiaDiscussão por: Dra. Amanda Chucre, Dra. Gabriele Ritter, Dr. Matheus Garcia, Dr. Pedro Moraes e Dr. Vinícius Molla
2025-08-1031 min
TMO EPM / Hemato H9J61 - Ruxolitinib in Patients With Corticosteroid-Refractory or Corticosteroid-Dependent Chronic Graft-Versus-Host Disease: 3-Year Final Analysis of the Phase III REACH3 StudyDiscussão do artigo: "Ruxolitinib in Patients With Corticosteroid-Refractory or Corticosteroid-Dependent Chronic Graft-Versus-Host Disease: 3-Year Final Analysis of the Phase III REACH3 Study" de Zeiser R JCO 2025Apresentado por: Dra. Amanda ChucreDiscussão por: Dra. Ana Cecilia Bahia, Dra. Ilana Barcessat, Dr. Pedro Moraes e Dr. Vinícius Molla
2025-08-0422 min
TMO EPM / Hemato H9J60 - Nivolumab-AVD Versus Brentuximab Vedotin–AVD in Older Patients With Advanced-Stage Classic Hodgkin Lymphoma Enrolled on S1826Discussão do artigo: "Nivolumab-AVD Versus BrentuximabVedotin–AVD in Older Patients With Advanced-Stage Classic Hodgkin Lymphoma Enrolled on S1826" de Rutherford S JCO 2025 Apresentado por: Dra. Ilana BarcessatDiscussão por: Dr. Eduardo Burlamaqui, Dr. Rafael Faust, Dr. Guilherme Rodrigues, Dr. Pedro Moraes e Dr. Vinícius Molla
2025-07-2733 min
TMO EPM / Hemato H9J59 - Intermediate-dose posttransplantation cyclophosphamide for myeloablative HLA-haploidentical bone marrow transplantationDiscussão do artigo: "Intermediate-dose posttransplantation cyclophosphamide for myeloablative HLA-haploidentical bone marrow transplantation" de Hyder M Blood Adv 2025Apresentado por: Dra. Amanda ChucreDiscussão por: Dra. Gabriele Ritter, Dr. Rafael Faust, Dr. Pedro Moraes e Dr. Vinícius Molla
2025-07-2322 min
TMO EPM / Hemato H9J58 - Ibrutinib plus venetoclax in relapsed or refractory mantle cell lymphoma (SYMPATICO): a multicentre, randomised,double-blind, placebo controlled, phase 3 studyDiscussão do artigo: "Ibrutinib plus venetoclax in relapsed or refractory mantle cell lymphoma (SYMPATICO): a multicentre, randomised, double-blind, placebo controlled, phase 3 study" de Wang M Lancet Oncology 2025Apresentado por: Dr. Guilherme RodriguesDiscussão por: Dr. Eduardo Burlamaqui, Dr. Lucas Salviano, Dr. Pedro Moraes e Dr. Vinícius Molla
2025-07-1334 min
TMO EPM / Hemato H9J57 - A randomized phase 2 trial of oral vitamin A for graft-versus-host disease in children and young adultsDiscussão do artigo: "A randomized phase 2 trial of oral vitamin A for graft-versus-host disease in children and young adults" de Khandelwal P Blood 2024Apresentado por: Dra. Lais ViannaDiscussão por: Dra. Gabriele Ritter, Dr. Rafael Faust, Dr. Pedro Moraes e Dr. Vinícius Molla
2025-07-0630 min
TMO EPM / Hemato H9J56 - Fixed-Duration Ibrutinib-Venetoclax in Patients with Chronic Lymphocytic Leukemia and ComorbiditiesDiscussão do artigo: "Fixed-Duration Ibrutinib-Venetoclax in Patients with Chronic Lymphocytic Leukemia and Comorbidities" de Kater A NEJM 2022Apresentado por: Dra. Ana Cecilia BahiaDiscussão por: Dr. Eduardo Burlamaqui, Dr. Lucas Salviano, Dr. Guilherme Rodrigues, Dr. Pedro Moraes e Dr. Vinícius Molla
2025-06-2935 min
TMO EPM / Hemato H9J55 - Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 MutationDiscussão do artigo: "Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation" de Stone R NEJM 2017Apresentado por: Dra. Lais ViannaDiscussão por: Dra. Gabriele Ritter, Dr. Rafael Faust, Dr. Pedro Moraes e Dr. Vinícius Molla
2025-06-2236 min
TMO EPM / Hemato H9J54 - Epcoritamab, a Novel, Subcutaneous CD3xCD20 Bispecific T-Cell–Engaging Antibody, in Relapsed or Refractory Large B-Cell Lymphoma: Dose Expansion in a Phase I/II TrialDiscussão do artigo: "Epcoritamab, a Novel, Subcutaneous CD3xCD20 Bispecific T-Cell–Engaging Antibody, in Relapsed or Refractory Large B-Cell Lymphoma: Dose Expansion in a Phase I/II Trial" de Thieblemont C JCO 2022Apresentado por: Dra. Ilana BarcessatDiscussão por: Dr. Eduardo Burlamaqui, Dr. Lucas Salviano, Dr. Guilherme Rodrigues, Dr. Pedro Moraes e Dr. Vinícius Molla
2025-06-0239 min
TMO EPM / Hemato H9J53 - Daratumumab, carfilzomib, lenalidomide, and dexamethasone with tandem transplant for high-risk newly diagnosed myelomaDiscussão do artigo: "Daratumumab, carfilzomib, lenalidomide, and dexamethasone with tandem transplant for high-risk newly diagnosed myeloma" de Touzeau C Blood 2024Apresentado por: Dr. Guilherme RodriguesDiscussão por: Dr. Eduardo Burlamaqui, Dr. Lucas Salviano, Dr. Rafael Faust e Dr. Vinícius Molla
2025-05-0231 min
TMO EPM / Hemato H9J52 - Nilotinib with or without cytarabine for Philadelphia-positive acute lymphoblastic leukemiaDiscussão do artigo: "Nilotinib with or without cytarabine for Philadelphia-positive acute lymphoblastic leukemia" de Chalandon Y Blood 2024Apresentado por: Dr. Matheus MaiaDiscussão por: Dra. Gabriele Ritter, Dr. Rafael Faust, Dra. Amanda Chucre, Dr. Pedro Moraes e Dr. Vinícius Molla
2025-04-2940 min
TMO EPM / Hemato H9J51 - Fixed-Duration Acalabrutinib Combinations in Untreated Chronic Lymphocytic LeukemiaDiscussão do artigo: "Fixed-Duration Acalabrutinib Combinations in Untreated Chronic Lymphocytic Leukemia" de Brown J NEJM 2025Apresentado por: Dra. Camila FradeDiscussão por: Dr. Lucas Salviano, Dr. Breno Aires, Dr. Rafael Faust, Dra. Camila Ferreira e Dr. Vinícius Molla
2025-04-1435 min
TMO EPM / Hemato H9J50 - Obecabtagene Autoleucel in Adults with B-Cell Acute Lymphoblastic LeukemiaDiscussão do artigo: "Obecabtagene autoleucel in adults with B-cell acute lymphoblastic leukemia" de Roddie C NEJM 2024Apresentado por: Dr. Gabriel CoquitoDiscussão por: Dr. Rafael Faust, Dra. Camila Ferreira e Dr. Pedro Moraes
2025-04-0726 min
TMO EPM / Hemato H9J49 - Zanubrutinib, obinutuzumab, and venetoclax for first-line treatment of mantle cell lymphoma with a TP53 mutationDiscussão do artigo: "Zanubrutinib, obinutuzumab, and venetoclax for first-line treatment of mantle cell lymphoma with a TP53 mutation" de Kumar A Blood 2025Apresentado por: Dr. Lucas SalvianoDiscussão por: Dr. Rafael Faust, Dra. Camila Ferreira e Dr. Vinicius Molla
2025-03-1835 min
TMO EPM / Hemato H9J48 - Talquetamab plus Teclistamab in Relapsed or Refractory Multiple MyelomaDiscussão do artigo: "Talquetamab plus Teclistamab in Relapsed or Refractory Multiple Myeloma" de Cohen Y NEJM 2025Apresentado por: Dr. Matheus PulsDiscussão por: Dr. Breno Aires, Dra. Camila Ferreira, Dr. Rafael Faust, Dr. Pedro Arruda e Dr. Vinicius Molla
2025-03-1626 min
TMO EPM / Hemato H9J47 - Daratumumab or Active Monitoring for High-Risk Smoldering Multiple MyelomaDiscussão do artigo: "Daratumumab or Active Monitoring for High-Risk Smoldering Multiple Myeloma" de Dimopoulos M NEJM 2024Apresentado por: Dra. Thais AraujoDiscussão por: Dr. Lucas Salviano, Dr. Breno Aires, Dr. Pedro Arruda e Dr. Vinicius Molla
2025-03-1132 min
TMO EPM / Hemato H9J46 - Daratumumab with lenalidomide as maintenance after transplant in newly diagnosed multiple myeloma: the AURIGA studyDiscussão do artigo: "Daratumumab with lenalidomide as maintenance after transplant in newly diagnosed multiple myeloma: the AURIGA study" de Badros A Blood 2024
Apresentado por: Dr. Matheus Puls
Discussão por: Dr. Rafael Faust, Dra. Camila Ferreira, Dr. Pedro Arruda e Dr. Vinicius Molla
2024-12-2935 min
TMO EPM / Hemato H9J45 - Isatuximab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple MyelomaDiscussão do artigo: "Isatuximab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma" de Facon T NEJM 2024
Apresentado por: Dra. Marcella Markman
Discussão por: Dr. Lucas Salviano, Dr. Breno Aires, Dr. Matheus Puls, Dr. Pedro Arruda e Dr. Vinicius Molla
2024-12-2630 min
TMO EPM / Hemato H9J44 - Single or Double Induction With 7 + 3 Containing Standard or High-Dose Daunorubicin for Newly Diagnosed AMLDiscussão do artigo: "Single or Double Induction With 7 + 3 Containing Standard or High-Dose Daunorubicin for Newly Diagnosed AML" de Rollig C JCO 2024
Apresentado por: Dra. Luana Pompeu
Discussão por: Dr. Rafael Faust, Dr. Breno Aires, Dr. Eurides Rosa, Dr. Pedro Arruda e Dr. Vinicius Molla
2024-12-2334 min
TMO EPM / Hemato H9J43 - Nivolumab+AVD in Advanced-Stage Classic Hodgkin’s LymphomaDiscussão do artigo: "Nivolumab+AVD in Advanced-Stage Classic Hodgkin’s Lymphoma" de Herrera AF NEJM 2024
Apresentado por: Dra. Aline Guerra
Discussão por: Dr. Lucas Salviano, Dr. Breno Aires, Dr. Pedro Arruda e Dr. Vinicius Molla
2024-11-2729 min
TMO EPM / Hemato H9J42 - Assessing the efficacy and tolerability of PET-guided BrECADD versus eBEACOPP in advanced-stage, classical Hodgkin lymphoma (HD21)Discussão do artigo: "Assessing the efficacy and tolerability of PET-guided BrECADD versus eBEACOPP in advanced-stage, classical Hodgkin lymphoma (HD21)" de Borchmann P Lancet 2024
Apresentado por: Dr. Gabriel Coquito
Discussão por: Dr. Rafael Faust, Dra. Camila Ferreira, Dr. Pedro Arruda e Dr. Vinicius Molla
2024-11-2336 min
TMO EPM / Hemato H9J41 - An international learning collaborative phase 2 trial for haploidentical bone marrow transplant in sickle cell diseaseDiscussão do artigo: "An international learning collaborative phase 2 trial for haploidentical bone marrow transplant in sickle cell disease" de Kassim A BLOOD 2024
Apresentado por:Dra. Aline Guerra
Discussão por: Dr. Rafael Faust, Dra. Camila Ferreira, Dr. Pedro Arruda e Dr. Vinicius Molla
2024-11-0127 min
TMO EPM / Hemato H9J40 - Autologous transplant vs. CAR-T therapy in patients with DLBCL treated while in complete remissionDiscussão do artigo: "Autologous transplant vs. CAR-T therapy in patients with DLBCL treated while in complete remission" de Shadman M Blood cancer journal 2024
Apresentado por: Dra. Camila Frade
Discussão por: Dr. Lucas Salviano, Dr. Breno Aires, Dr. Pedro Arruda e Dr. Vinicius Molla
2024-09-2720 min
TMO EPM / Hemato H9J39 - Post-Transplant Cyclophosphamide–Based Graft-Versus-Host Disease Prophylaxis Attenuates Disparity in Outcomes Between Use of Matched or Mismatched Unrelated DonorsDiscussão do artigo: "Post-Transplant Cyclophosphamide–Based Graft-Versus-Host Disease Prophylaxis Attenuates Disparity in Outcomes Between Use of Matched or Mismatched Unrelated Donors" de Shaffer B JCO 2024
Apresentado por: Dra. Marcela Markmann
Discussão por: Dr. Rafael Faust, Dra. Camila Ferreira, Dr. Pedro Arruda e Dr. Vinicius Molla
2024-09-2530 min
TMO EPM / Hemato H9J38 - Belantamab Mafodotin, Bortezomib, and Dexamethasone for Multiple MyelomaDiscussão do artigo: "Belantamab Mafodotin, Bortezomib, and Dexamethasone for Multiple Myeloma" de Hungria V NEJM 2024
Apresentado por: Dr. Matheus Puls
Discussão por: Dr. Lucas Salviano, Dr. Breno Aires, Dra. Aline Guerra, Dr. Pedro Arruda e Dr. Vinicius Molla
2024-09-1940 min
TMO EPM / Hemato H9J37 - Blinatumomab for MRD-Negative Acute Lymphoblastic Leukemia in AdultsDiscussão do artigo: "Blinatumomab for MRD-Negative Acute Lymphoblastic Leukemia in Adults" de Litzow MR NEJM 2024
Apresentado por: Dr. Gabriel Coquito
Discussão por: Dr. Lucas Salviano, Dra. Camila Ferreira, Dr. Pedro Arruda e Dr. Vinicius Molla
2024-08-2534 min
TMO EPM / Hemato H9J36 - Combination Targeted Therapy in Relapsed Diffuse Large B-Cell LymphomaDiscussão do artigo: "Combination Targeted Therapy in Relapsed Diffuse Large B-Cell Lymphoma" de Melani C NEJM 2024
Apresentado por: Dra. Aline Guerra
Discussão por: Dr. Lucas Salviano, Dr. Breno Aires, Dr. Pedro Arruda e Dr. Vinicius Molla
2024-08-1624 min
TMO EPM / Hemato H9J35 - A multicenter study of posttransplantation low-dose inotuzumab ozogamicin to prevent relapse of acute lymphoblastic leukemiaDiscussão do artigo: "A multicenter study of posttransplantation low-dose inotuzumab ozogamicin to prevent relapse of acute lymphoblastic leukemia" de Metheny L Blood Adv. 2024 Mar 26;8(6):1384-1391
Apresentado por: Dra. Thais Araujo
Discussão por: Dr. Rafael Faust, Dra. Camila Ferreira, Dr. Pedro Arruda e Dr. Vinicius Molla
2024-08-0524 min
TMO EPM / Hemato H9J34 - Postinduction molecular MRD identifies patients with NPM1 AML who benefit from allogeneic transplant in first remissionDiscussão do artigo: "Postinduction molecular MRD identifies patients with NPM1 AML who benefit from allogeneic transplant in first remission " de Othman J Blood 2024
Apresentado por: Dra. Luana Pompeu
Discussão por: Dr. Rafael Faust, Dra. Camila Ferreira, Dr. Pedro Arruda e Dr. Vinicius Molla
2024-07-2728 min
TMO EPM / Hemato H9J33 - Asciminib in Newly Diagnosed Chronic Myeloid LeukemiaDiscussão do artigo: "Asciminib in Newly Diagnosed Chronic Myeloid Leukemia" de Hochhaus A NEJM 2024
Apresentado por: Dra. Camila Frade
Discussão por: Dr. Lucas Salviano, Dra. Camila Ferreira, Dr. Pedro Arruda e Dr. Vinicius Molla.
2024-07-1531 min
TMO EPM / Hemato H9J32 - The addition of bortezomib to rituximab, high-dose cytarabine and dexamethasone in relapsed or refractory mantle cell lymphoma—a randomized, open-label phase III trialDiscussão do artigo: "Outcomes of allogeneic hematopoietic stem cell transplantation for relapsed or refractory diffuse large B-cell lymphoma" de Koji Kato Bone Marrow Transplantation 2024
Apresentado por: Dra Marcella Markman
Discussão por: Dr. Rafael Faust, Dra. Camila Ferreira, Dr. Pedro Arruda e Dr. Vinicius Molla
2024-07-1233 min
TMO EPM / Hemato H9J31 - Remission induction vs immediate allogeneic HSCT for patients with relapsed or poor responsive AML (ASAP): a randomised, open-label, phase 3, non-inferiority trialDiscussão do artigo: "Remission induction versus immediate allogeneic haematopoietic stem cell transplantation for patients with relapsed or poor responsive acute myeloid leukaemia (ASAP): a randomised, open-label, phase 3, non-inferiority trial" de Stelljes M Lancet Haematol 2024.
Apresentado por: Dr Gabriel Coquito
2024-07-0520 min
TMO EPM / Hemato H9J30 - Ibrutinib combined with immunochemotherapy with or without ASCT vs immunochemotherapy and ASCT in previously untreated patients with mantle cell lymphoma (TRIANGLE)Discussão do artigo: "Ibrutinib combined with immunochemotherapy with or without autologous stem-cell transplantation versus immunochemotherapy and autologous stem-cell transplantation in previously untreated patients with mantle cell lymphoma (TRIANGLE)" de Dreyling M Lancet 2024; 403: 2293–306
Apresentado por: Dra Thais Araujo
Discussão por: Dr. Lucas Salviano, Dr. Breno Aires, Dr. Pedro Arruda e Dr. Vinicius Molla.
2024-07-0333 min
TMO EPM / Hemato H9J29 - Younger unrelated donors may be preferable over HLA match in the PTCy era: A study from the ALWP of the EBMTDiscussão do artigo: "Younger unrelated donors may be preferable over HLA match in the PTCy era: A study from the ALWP of the EBMT" de Sanz J Blood 2024
Apresentado por: Dra Luana Pompeu
Discussão por: Dr. Lucas Salviano, Dr. Breno Aires, Dr. Gabriel Coquito, Dr. Pedro Arruda e Dr. Vinicius Molla.
2024-05-2722 min
TMO EPM / Hemato H9J28 - Nonrestrictive diet does not increase infections during post-HSCT neutropenia: data from a multicenter randomized trialDiscussão do artigo: "Nonrestrictive diet does not increase infections during post-HSCT neutropenia: data from a multicenter randomized trial" de Stella F Blood Advances 2023
Apresentado por: Dra Camila Frade
Discussão por: Dr. Lucas Salviano, Dr. Breno Aires, Dr. Matheus Puls, Dr. Pedro Arruda e Dr. Vinicius Molla.
2024-04-2423 min
TMO EPM / Hemato H9J27 - Outcomes of allogeneic hematopoietic stem cell transplantation for relapsed or refractory diffuse large B-cell lymphomaDiscussão do artigo: "Outcomes of allogeneic hematopoietic stem cell transplantation for relapsed or refractory diffuse large B-cell lymphoma" de Koji Kato Bone Marrow Transplantation 2024
Apresentado por: Dra Aline Guerra
Discussão por: Dra. Camila Ferreira, Dr. Rafael Faust, Dr. Matheus Puls, Dr. Pedro Arruda e Dr. Vinicius Molla
2024-04-1430 min
TMO EPM / Hemato H9J26 - Gilteritinib as Post-Transplant Maintenance for Acute Myeloid Leukemia With Internal Tandem Duplication Mutation of FLT3Discussão do artigo: "Gilteritinib as Post-Transplant Maintenance for Acute Myeloid Leukemia With Internal Tandem Duplication Mutation of FLT3" de Levis M J Clin Oncol 2024
Apresentado por: Dra Marcella Markman
Discussão por: Dr. Lucas Salviano, Dr. Breno Aires, Dr. Matheus Puls, Dr. Gabriel Coquito, Dr. Pedro Arruda e Dr. Vinicius Molla.
2024-04-0630 min
TMO EPM / Hemato H9J25 - PTCy versus ATG after RIC peripheral blood allogeneic cell transplantation in recipients of matched sibling or 10/10 HLA matched unrelated donorsDiscussão do artigo: "PTCy versus ATG after RIC peripheral blood allogeneic cell transplantation in recipients of matched sibling or 10/10 HLA matched unrelated donors: final analysis of a randomized, open-label, multicenter, phase 2 trial" de Brissot E Blood Cancer Journal 2024
Apresentado por: Dra Thaís Araújo
Discussão por: Dra. Camila Ferreira, Dr. Rafael Faust, Dr. Pedro Arruda, Dr. Vinicius Molla e Dr. Eurides Rosa.
2024-03-2832 min
TMO EPM / Hemato H9J24 - Oral decitabine and cedazuridine plus venetoclax for older or unfit patients with acute myeloid leukaemia: a phase 2 studyDiscussão do artigo: "Oral decitabine and cedazuridine plus venetoclax for older or unfit patients with acute myeloid leukaemia: a phase 2 study" de Bazinet A Lancet Haematol 2024
Apresentado por: Dr Gabriel Coquito
Discussão por: Dr. Lucas Salviano, Dr. Breno Aires, Dra. Aline Guerra, Dr. Pedro Arruda e Dr. Vinicius Molla.
2024-03-2530 min
TMO EPM / Hemato H9J23 - Subcutaneous daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone in patients with relapsed or refractory multiple myeloma (APOLLO): extended follow upDiscussão do artigo: "Subcutaneous daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone in patients with relapsed or refractory multiple myeloma (APOLLO): extended follow up" de Dimopoulos M Lancet Haematol 2023
Apresentado por: Dra Luana Pompeu
Discussão por: Dra. Camila Ferreira, Dr. Matheus Puls, Dr. Gabriel Coquito, Dr. Pedro Arruda, Dr. Vinicius Molla e Dra. Roberta Szor.
2024-03-1624 min
TMO EPM / Hemato H9J22 - Tacrolimus /methotrexate vs tacrolimus / reduced-dose methotrexate / mycophenolate for graft-versus-host disease preventionDiscussão do artigo: "Tacrolimus /methotrexate vs tacrolimus / reduced-dose methotrexate / mycophenolate for graft-versus-host disease prevention" de Hamilton B Blood advances 2023
Apresentado por: Dr. Carlos Rivera
Discussão por: Dr. Breno Aires, Dra. Thais Araujo, Dr. Diego Luz, Dra. Fernanda Azevedo, Dr. Eurides Rosa, Dr. Caio Justino e Dr. Vinicius Molla.
2024-03-0327 min
TMO EPM / Hemato H9J21 - Long-term outcomes of patients with large B-cell lymphoma treated with axicabtagene ciloleucel and prophylactic corticosteroidsDiscussão do artigo: "Long-term outcomes of patients with large B-cell lymphoma treated with axicabtagene ciloleucel and prophylactic corticosteroids" de Oluwole O BMT 2024
Apresentado por: Dr. Caio Prato
Discussão por: Dra. Camila Ferreira, Dr. Matheus Puls, Dr. Eurides Rosa, Dr. Pedro Arruda e Dr. Vinicius Molla.
2024-02-2926 min
TMO EPM / Hemato H9J20 - Azacitidine, Venetoclax, and Gilteritinib in Newly Diagnosed and Relapsed or Refractory FLT3-Mutated AMLDiscussão do artigo: "Azacitidine, Venetoclax, and Gilteritinib in Newly Diagnosed and Relapsed or Refractory FLT3-Mutated AML" de Short NJ J Clin Oncol 2024 Jan 26
Apresentado por: Dra. Fernanda Azevedo
Discussão por: Dr. Breno Aires, Dra. Thais Araujo, Dr. Caio Prato, Dra. Eurides Rosa, Dr. Pedro Arruda e Dr. Vinicius Molla.
2024-02-1730 min
TMO EPM / Hemato H9J19 - Zanubrutinib Versus Ibrutinib in Symptomatic Waldenstrom Macroglobulinemia: Final Analysis From the Randomized Phase III ASPEN StudyDiscussão do artigo: "Zanubrutinib Versus Ibrutinib in Symptomatic Waldenstrom Macroglobulinemia: Final Analysis From the Randomized Phase III ASPEN Study" de Dimopoulos M JCO 2023.
Apresentado por: Dr. Pedro Flores
Discussão por: Dra. Camila Ferreira, Dr. Matheus Puls, Dr. Diego Luz, Dr. Pedro Arruda e Dr. Vinicius Molla.
2024-02-0427 min
TMO EPM / Hemato H9J18 - Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple MyelomaDiscussão do artigo: "Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma" de Sonneveld P NEJM 2023
Apresentado por: Dr. Pedro Flores
Discussão por: Dr. Breno Aires, Dra. Thais Araujo, Dr. Diego Luz, Dra. Fernanda Azevedo, Dra. Roberta Szor, Dr. Pedro Arruda e Dr. Vinicius Molla.
2024-01-2936 min
TMO EPM / Hemato H9J17 - Chronic Lymphocytic Leukemia Therapy Guided by Measurable Residual DiseaseDiscussão do artigo: "Chronic Lymphocytic Leukemia Therapy Guided by Measurable Residual Disease" de Munir t NEJM 2023.
Apresentado por: Dr. Diego Luz
Discussão por: Dra. Camila Ferreira, Dr. Matheus Puls, Dr. Pedro Flores, Dr. Pedro Arruda e Dr. Vinicius Molla.
2024-01-1426 min
TMO EPM / Hemato H9J16 - Prognostic Value of FLT3-Internal Tandem Duplication Residual Disease in AMLDiscussão do artigo: "Prognostic Value of FLT3-Internal Tandem Duplication Residual Disease in AML" de Grob t Clin Oncol 41:756-765.
Apresentado por: Dra. Fernanda Azevedo
Discussão por: Dr. Breno Aires, Dra. Thais Araujo, Dr. Caio Prato, Dr. Pedro Flores, Dr. Diego Luz, Dr. Eurides Rosa, Dr. Pedro Arruda e Dr. Vinicius Molla.
2023-12-1734 min
TMO EPM / Hemato H9J15 - Prophylactic versus Preemptive modified donor lymphocyte infusion for high-risk acute leukemia after allogeneic hematopoietic stem cell transplantationDiscussão do artigo: "Prophylactic versus Preemptive modified donor lymphocyte infusion for high-risk acute leukemia after allogeneic hematopoietic stem cell transplantation" de Yang L BMT 2023.
Apresentado por: Dra. Nicole Marques
Discussão por: Dra. Camila Ferreira, Dr. Matheus Puls, Dr. Caio Prato, Dr. Carlos Rivera, Dr. Pedro Arruda e Dr. Vinicius Molla.
2023-12-0326 min
TMO EPM / Hemato H9J14 - BuFlu vs BuCy for AML Undergoing HLA-Haploidentical Hematopoietic Cell Transplantation: A Multicenter Randomized Phase III TrialDiscussão do artigo: "BuFlu vs BuCy for AML Undergoing HLA-Haploidentical Hematopoietic Cell Transplantation: A Multicenter Randomized Phase III Trial" de Ling Y J Clin Oncol 2023 41:4632-4642
Apresentado por: Dr. Pedro Flores
Discussão por: Dr. Breno Aires, Dra. Thais Araujo, Dr. Diego Luz, Dra. Nicole Marques, Dr. Pedro Arruda, Dr. Vinicius Molla e Dr. Eurides Rosa.
2023-11-2628 min
TMO EPM / Hemato H9J13 - R-CODOX-M/R-IVAC versus DA-EPOCH-R in patients with newly diagnosed Burkitt lymphomaDiscussão do artigo: "R-CODOX-M/R-IVAC versus DA-EPOCH-R in patients with newly diagnosed Burkitt lymphoma" de Chamuleau MED Lancet Haematol 2023
Apresentado por: Dr. Diego Luz
Discussão por: Dra. Camila Ferreira, Dr. Matheus Puls, Dr. Diego Luz, Dr. Pedro Flores, Dr. Pedro Arruda, Dr. Vinicius Molla, Dr. Eurides Rosa e Dr. Celso Arrais.
2023-11-1928 minTMO EPM / Hemato H9J12 - PTCy, abatacept, and a short course of tacrolimus for GVHD prevention after haploidentical transplantationDiscussão do artigo: "PTCy, abatacept, and a short course of tacrolimus for GVHD prevention after haploidentical transplantation" de Al-Homsi A Blood Adv (2023) 7 (14): 3604–3611.
Apresentado por: Dr. Carlos Rivera
Discussão por: Dr. Breno Aires, Dra. Thais Araujo, Dr. Diego Luz, Dr. Pedro Arruda, Dr. Vinicius Molla e Dr. Eurides Rosa.
2023-11-1342 min
TMO EPM / Hemato H9J11 - Minimal residual disease response-adapted therapy in newly diagnosed multiple myeloma (MASTER)Discussão do artigo: "Minimal residual disease response-adapted therapy in newly diagnosed multiple myeloma (MASTER)" de Costa L, Lancet Haematol 2023.
Apresentado por: Dra. Fernanda Azevedo
Discussão por: Dra. Camila Ferreira, Dr. Matheus Puls, Dr. Caio Prato, Dr. Pedro Arruda, Dr. Vinicius Molla e Dr. Celso Arrais.
2023-10-2234 min
TMO EPM / Hemato H9J10 - Ide-cel or Standard Regimens in Relapsed and Refractory Multiple MyelomaDiscussão do artigo: "Ide-cel or Standard Regimens in Relapsed and Refractory Multiple Myeloma" de Rodriguez‐Otero P, N Engl J Med 2023;388:1002-14
Apresentado por: Dr. Diego Luz
Discussão por: Dra. Camila Ferreira, Dr. Matheus Puls, Dra. Thais Araujo, Dra. Fernanda Azevedo, Dr. Pedro Arruda e Dra. Roberta Szor.
2023-10-0832 min
TMO EPM / Hemato H9J09 - Sirolimus versus cyclosporine in haploidentical stem cell transplantation with posttransplant cyclophosphamide and mycophenolate mofetil as graft-versus-host disease prophylaxisDiscussão do artigo: "Sirolimus versus cyclosporine in haploidentical stem cell transplantation with posttransplant cyclophosphamide and mycophenolate mofetil as graft-versus-host disease prophylaxis" de Hernani R, eJHaem. 2021;2:236–248
Apresentado por: Dr. Carlos Rivera
Discussão por: Dra. Camila Ferreira, Dr. Matheus Puls, Dra. Fernanda Azevedo, Dr. Pedro Arruda e Dr. Vinícius Molla.
2023-10-0227 min
TMO EPM / Hemato H9J08 - Long-term follow-up of rituximab plus bendamustine and cytarabine in older patients with newly diagnosed MCLDiscussão do artigo: "Long-term follow-up of rituximab plus bendamustine and cytarabine in older patients with newly diagnosed MCL" de Tisi M, Blood Adv (2023) 7 (15): 3916–3924.
Apresentado por: Dr. Caio Prato
Discussão por: Dr. Celso Arrais, Dr. Breno Aires, Dr. Pedro Flores, Dr. Pedro Arruda e Dr. Vinícius Molla.
2023-09-2424 min
TMO EPM / Hemato H9J07 - Treosulfan compared with reduced-intensity busulfan improves allogeneic hematopoietic cell transplantation outcomes of older acute myeloid leukemia and myelodysplastic syndrome patientsDiscussão do artigo: "Treosulfan compared with reduced-intensity busulfan improves allogeneic hematopoietic cell transplantation outcomes of older acute myeloid leukemia and myelodysplastic syndrome patients" de Beelen D, Am J Hematol. 2022;97:1023–1034.
Apresentado por: Dra. Nicole Marques
Discussão por: Breno Aires, Thais Araujo, Ana Paula Tavares, Pedro Arruda, e Vinícius Molla.
2023-08-2823 min
TMO EPM / Hemato H9J06 - Survival with Axicabtagene Ciloleucel in Large B-Cell LymphomaDiscussão do artigo: "Survival with Axicabtagene Ciloleucel in Large B-Cell Lymphoma" de Jason R. Westin, N Engl J Med 2023; 389:148-157
Apresentado por: Dr. Pedro Flores
Discussão por: Camila Ferreira, Matheus Puls, Nicole Marques, Pedro Arruda, Roberta Szor e Vinícius Molla.
2023-08-1931 min
TMO EPM / Hemato H9J05 - Sorafenib maintenance after allogeneic haemopoietic stem-cell transplantation in patients with FLT3-ITD AML: long-term follow-up of an open-label, multicentre, randomised, phase 3Discussão do artigo: "Sorafenib maintenance after allogeneic haemopoietic stem-cell transplantation in patients with FLT3-ITD acute myeloid leukaemia: long-term follow-up of an open-label, multicentre, randomised, phase 3 trial" de Xuan L, Lancet Haematol 2023; 10: 600–11.
Apresentado por: Caio Prato
Discussão por: Breno Aires, Fernanda Azevedo, Thais Araujo, Pedro Flores, Pedro Arruda, Roberta Szor e Vinícius Molla.
2023-08-1231 min
TMO EPM / Hemato H9J04 - Defibrotide plus best standard of care compared with best standard of care alone for the prevention of sinusoidal obstruction syndrome (HARMONY): a randomised, multicentre, phase 3Discussão do artigo: "Defibrotide plus best standard of care compared with best standard of care alone for the prevention of sinusoidal obstruction syndrome (HARMONY): a randomised, multicentre, phase 3" de Stephan A Grupp, Lancet Haematol, March 28, 2023.
Apresentado por: Fernanda Azevedo
Discussão por: Camila Ferreira, Celso Arrais, Matheus Puls, Thais Fernanda, Pedro Arruda e Vinícius Molla.
2023-08-0532 min
TMO EPM / Hemato H9J03 - Eltrombopag for Low-Risk Myelodysplastic Syndromes With Thrombocytopenia: Interim Results of a Phase-II, Randomized, Placebo-Controlled Clinical Trial (EQOL-MDS)Discussão do artigo: "Eltrombopag for Low-Risk Myelodysplastic Syndromes With Thrombocytopenia: Interim Results of a Phase-II, Randomized, Placebo-Controlled Clinical Trial (EQOL-MDS)" de Esther Natalie Oliva, Journal of Clinical Oncology 2023.
Apresentado por: Nicole Marques
Discussão por: Breno Aires, Diego Luz, Matheus Puls, Pedro Flores, Thais Fernanda, Pedro Arruda e Vinícius Molla.
2023-07-2925 min
TMO EPM / Hemato H9JDecitabine Versus Hydroxyurea for Advanced Proliferative Chronic Myelomonocytic Leukemia: Results of a Randomized Phase III Trial Within the EMSCO NetworkDiscussão do artigo: "Decitabine Versus Hydroxyurea for Advanced Proliferative Chronic Myelomonocytic Leukemia: Results of a Randomized Phase III Trial Within the EMSCO Network" de Raphael Itzykson, Journal of Clinical Oncology 41, no. 10 (April 01, 2023) 1888-1897.
Apresentado por Pedro Flores
Discussão por: Breno Aires, Diego Luz, Fernanda Azevedo, Matheus Puls, Pedro Arruda e Vinícius Molla.
2023-07-2128 min
TMO EPM / Hemato H9JAlternative donor BMT with posttransplant cyclophosphamide as initial therapy for acquired severe aplastic anemiaDiscussão do artigo "Alternative donor BMT with posttransplant cyclophosphamide as initial therapy for acquired severe aplastic anemia" de Amy E DeZern, publicado Blood. 2023 Jun 22;141(25):3031-3038. doi: 10.1182/blood.2023020435.
Apresentado pelo Dr Diego Luz
2023-07-1608 min